EraGen Said to Develop SARS Diagnostic; Solicits Validation

EraGen Biosciences has used its Gene-Code technology to develop a diagnostic for severe acute respiratory syndrome, and has begun shipping the test to the World Health Organization and the British Columbia Center for Disease Control, the company said last week.

EraGen is also developing a genotyping assay to differentiate the SARS strains sequenced to date.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.